While the health authorities are concerned about a decline in the level of protection after the first injections, Spikevax is the second reminder to receive the green light after the Pfizer-Biontech vaccine at the beginning of the month.
Le Monde with AFP
The French health authorities were waiting for the green light. The European Medicines Agency (AEM) finally approved, Monday, October 25, the administration of recall doses of the Non-Covid-19 vaccine of the modern laboratory, to the 18-year-olds and over. The opinion intervenes, while the health authorities are concerned about a decrease in the level of protection after the first injections.
Spikevax is the second reminder to receive the green light after the Pfizer-Biontech vaccine at the beginning of the month. “The data showed that a third dose of Spikevax administered six to eight months after the second dose led to an increase in antibody levels in adults whose antibody levels decreased,” said the AEM.
similar side effects
The health authorities of the twenty-seven EU members “may issue official recommendations on the use of recall doses, taking into account the local epidemiological situation,” said the monitoring agency, SIS in Amsterdam.
The Agency specifies that the current data show a scheme of side effects similar to that which followed the second dose of Spikevax. “The risk of inflammatory heart disorders and other very rare side effects after a reminder is carefully monitored,” continues the AEM.